Comparison of Betaferon, Avonex, and Rebif in treatment of relapsing-remitting multiple sclerosis
Author:
Publisher
Wiley
Subject
Neurology (clinical),Neurology,General Medicine
Link
http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1600-0404.2006.00585.x/fullpdf
Reference23 articles.
1. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG);Jacobs;Ann Neurol,1996
2. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group;Lancet,1998
3. Therapeutic advances: interferon for multiple sclerosis;Clark;J Clin Pharm Ther,1996
4. Management of patients receiving interferon β-1b for multiple sclerosis: report of a consensus conference;Lublin;Neurology,1996
5. Interferon β-1b is effective in relapsing-remitting multiple sclerosis: I. Clinical results of a multi-centre, randomized, double-blind, placebo-controlled trial;The IFN-β Multiple Sclerosis Study Group;Neurology,1993
Cited by 47 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Do efficacy results obtained from randomized controlled trials translate to effectiveness data from observational studies for relapsing–remitting multiple sclerosis?;Pharmacoepidemiology and Drug Safety;2024-05
2. Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysis;Cochrane Database of Systematic Reviews;2024-01-04
3. Disease-modifying therapies;Clinical Aspects of Multiple Sclerosis Essentials and Current Updates;2024
4. Adverse effects of immunotherapies for multiple sclerosis: a network meta-analysis;Cochrane Database of Systematic Reviews;2023-11-30
5. Comparative efficacy and safety of disease-modifying therapies in patients with relapsing multiple sclerosis: A systematic review and network meta-analysis;Journal of the American Pharmacists Association;2023-01
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3